Research Analysts Set Expectations for KNSA Q2 Earnings

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) – Stock analysts at Wedbush decreased their Q2 2025 EPS estimates for shares of Kiniksa Pharmaceuticals in a report released on Tuesday, April 29th. Wedbush analyst D. Nierengarten now anticipates that the company will earn $0.24 per share for the quarter, down from their prior forecast of $0.38. Wedbush has a “Outperform” rating and a $34.00 price target on the stock. The consensus estimate for Kiniksa Pharmaceuticals’ current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q3 2025 earnings at $0.25 EPS, Q4 2025 earnings at $0.28 EPS, FY2025 earnings at $0.89 EPS, FY2026 earnings at $1.48 EPS, FY2027 earnings at $1.98 EPS and FY2028 earnings at $2.31 EPS.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm had revenue of $137.79 million during the quarter, compared to analysts’ expectations of $128.35 million. During the same period in the previous year, the company earned ($0.25) EPS. Kiniksa Pharmaceuticals’s revenue for the quarter was up 72.5% on a year-over-year basis.

KNSA has been the topic of a number of other research reports. Citigroup began coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They set a “buy” rating and a $40.00 price objective on the stock. Jefferies Financial Group boosted their price objective on Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals presently has an average rating of “Buy” and an average price target of $38.00.

Kiniksa Pharmaceuticals Stock Performance

KNSA opened at $27.74 on Friday. The company has a market capitalization of $2.02 billion, a P/E ratio of -198.13 and a beta of 0.31. The company has a 50-day moving average of $21.61 and a 200-day moving average of $21.35. Kiniksa Pharmaceuticals has a 1-year low of $17.38 and a 1-year high of $28.15.

Insider Activity

In related news, CAO Michael R. Megna sold 9,051 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total value of $203,194.95. Following the transaction, the chief accounting officer now owns 26,528 shares in the company, valued at approximately $595,553.60. This represents a 25.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Mark Ragosa sold 8,879 shares of the stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $23.10, for a total transaction of $205,104.90. Following the completion of the sale, the chief financial officer now directly owns 23,382 shares in the company, valued at approximately $540,124.20. The trade was a 27.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 218,548 shares of company stock worth $5,210,745. Company insiders own 54.57% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. purchased a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter valued at about $4,997,000. SG Americas Securities LLC bought a new stake in Kiniksa Pharmaceuticals in the fourth quarter worth about $355,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Kiniksa Pharmaceuticals by 36.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 122,019 shares of the company’s stock valued at $2,414,000 after purchasing an additional 32,393 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Kiniksa Pharmaceuticals in the 4th quarter valued at about $3,955,000. Finally, Globeflex Capital L P raised its holdings in Kiniksa Pharmaceuticals by 217.1% in the fourth quarter. Globeflex Capital L P now owns 88,596 shares of the company’s stock worth $1,752,000 after purchasing an additional 60,656 shares in the last quarter. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.